bjgabrielsen

Higher Radiation Therapy Doses Over Shorter Time Show No Added Side Effects in Men with Prostate Cancer.

Delivering higher doses of radiation therapy over a shorter time period — an approach called stereotactic body radiation therapy (SBRT) — does not worsen side effects in men with localized prostate cancer, compared to conventional radiation therapy, a Phase 3 trial shows. The study also suggests that SBRT delivered through the CyberKnife System is less more »

From Prostvac to Fear Then to Faith

As many of you readers know, I have earlystage, asymptomatic but advanced prostate cancer. After treatment with Provenge, I was informed (perhaps divinely through a former colleague) of a National Cancer Institute (NCI) clinical trial currently recruiting patients like myself. The protocol involves treatment with the vaccine Prostvac and the antibody therapy, Opdivo. I had written more »

PSMA PET-CT Offers Best Detection Rates in Recurrent Prostate Cancer.

In a recent study, investigators reported the findings of a clinical trial designed to compare the rates for detecting recurrent cancer sites using the prostate-specific membrane antigen (PSMA) PET-CT imaging agent (68Ga-PSMA-11) to those of 18F-fluciclovine in a group of men with recurrent prostate cancer who had already undergone prostatectomy and had very low levels more »

FDA Approves Erleada to Treat Metastatic Castration-sensitive Prostate Cancer

The U.S. Food and Drug Administration (FDA) has approved Erleada (apalutamide) for the treatment of men with metastatic, castration (hormone)-sensitive prostate cancer (mCSPC), or those whose cancer still responds to androgen deprivation (hormonal) therapy (ADT). The decision is based on the double-blind TITAN Phase 3 trial (NCT02489318), as it showed that adding Janssen’s Erleada to more »

PSMA-Targeted Therapies Work Best in Tumors With Mutations in DNA Repair Genes.

Tumors with large numbers of prostate cancer cells with mutations in DNA repair genes (e.g. BRCA1 and 2) are easier to target using prostate-specific membrane antigen (PSMA) therapies, and patients with these tumors are more likely to respond to this potential treatment’s use, a study found and published in European Urology. PSMA is a membrane more »

Breast, Ovarian Cancer Drug Delays Progression in Advanced Prostate Cancer Patients with Specific Mutations.

Men with metastatic hormone-resistant prostate cancer (mCRPC) given Lynparza® (olaparib), a breast and ovarian cancer treatment, lived a clinically meaningful longer time without disease progression or death compared to those given standard treatment with Xtandi® (enzalutamide) or Zytiga® (abiraterone) in a Phase 3 trial. These eligible patients had a mutation in one of 15 DNA more »

PyL Imaging Agent Detects Lesions Outside the Prostate in a Phase 2/3 Trial

In a Phase 2/3 OSPREY clinical trial aimed at examining its diagnostic accuracy, 18F-DCFPyl (PyL), a new imaging agent for positron emission topography (PET) scans, can accurately detect prostate cancer lesions outside the prostate, whether in nearby lymph nodes or in distant locations, clinical trial data show. The tracer — developed by Progenics — is a more »

68-Gallium PSMA PET Scan Better Than Axumin in Detecting Cancer Recurrence

Among men suspected of having prostate cancer recurrence after surgery, the radiotracer 68Ga-PSMA-11 is better at detecting the cancerous lesions and provides better agreement among experts than the standard Axumin (18F-fluciclovine) tracer, a Phase 2 trial shows. The results were presented at the 2019 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, held more »

Treatments for Men with Metastatic, Hormone-Sensitive Prostate Cancer

The treatment landscape for metastatic prostate cancer is shifting and expanding yet again, according to new findings from two large clinical trials presented at the 2019 annual meeting of the American Society of Clinical Oncology (ASCO). The ENZAMET trial tested the drug enzalutamide (Xtandi) and the TITAN trial tested apalutamide (Erleada) in men whose cancer more »

2019 Prostate Cancer Guide from the Prostate Cancer Foundation – a Great Guide.

Here is the 2019 guide from the Prostate Cancer Foundation. Section One deals with General Information and Medical Basics. Section Two provides valuable information for those who are newly diagnosed. Section Three describes treatment options for localized or locally advanced prostate cancer. Section Four discusses aspects of living with and after prostate cancer. This guide more »

Weekly Prostate Cancer Videos from the Prostate Cancer Research Institute

Earlier this year, a series of informative videos dealing with several prostate cancer topics were produced by the Prostate Cancer Research Institute (PCRI). These included:\ 1. The Best Prostate Cancer Diet by Dr. Mark Moyad; 2. HDR Brachytherapy (temporary seeds) for Intermediate Risk by Dr. Mark Scholz: 3. How Immune Therapy Works to Treat Prosate more »

Study Suggests Enzalutamide (Xtandi) Better and Cheaper Than Abiraterone (Zytiga) for Metastatic, Hormone-Resistant Prostate Cancer.

A recent study presented on May 3-6 at the American Urological Association’s 2019 Meeting found that treating metastatic, hormone-resistant prostate cancer (mCRPC) patients (who had not received chemotherapy) with Xtandi (enzalutamide) leads to better survival outcomes and lower healthcare costs than Zytiga (abiraterone acetate). While therapies that lower male sex hormones (testosterone) — required for more »

Radioactive Lutetium-177 Compound Shows Promise As Therapy For Metastatic, Hormone-Resistant Prostate Cancer.

Treatment with the radioactive molecule lutetium-177-PSMA-617 (LuPSMA), which binds to the prostate-specific membrane antigen, is a potential therapeutic strategy for patients with metastatic castration (hormone)-resistant prostate cancer (CRPC), results from a Phase II pilot study suggest. Prostate-specific membrane antigen (PSMA) is found at high levels in prostate cancers, particularly in patients with hormone-resistant disease — more »